The Hetero Ring Has At Least Seven Members Patents (Class 514/450)
-
Publication number: 20140005259Abstract: Pharmaceutical or dermo-dermo-cosmetic compositions for topical and intravaginal application for treatment of human and veterinary affections caused by anaerobic organisms or parasites comprising quassinoids or plant extracts containing these phytochemicals, in effective amounts. Such compositions can be administered topically or intravaginally to patients in need thereof in various pharmaceutical dosage forms.Type: ApplicationFiled: August 29, 2013Publication date: January 2, 2014Applicant: LIFE SCIENCE INVESTMENTS LIMITEDInventors: Christian DIEHL, Silvia CHAMI DE DIEHL
-
Publication number: 20130344012Abstract: A metathesized natural oil composition comprising (i) a mixture olefins and/or esters, or (ii) a metathesized natural oil, is disclosed. The metathesized natural oil composition has a number average molecular weight in the range from about 100 g/mol to about 150,000 g/mol, a weight average molecular weight in the range from about 1,000 g/mol to about 100,000 g/mol, a z-average molecular weight in the range from about 5,000 g/mol to about 1,000,000 g/mol, and a polydispersity index of about 1 to about 20. The metathesized natural oil composition is metathesized at least once.Type: ApplicationFiled: June 20, 2013Publication date: December 26, 2013Inventors: Steven A. Cohen, M. Michelle Morie-Bebel, Alexander D. Ilseman, Benjamin Bergmann, Stephen A. DiBiase, S. Alexander Christensen
-
Publication number: 20130345164Abstract: This invention concerns methods of identifying treatments for treating various disorders and related computer products and systems. Also disclosed are methods for treating cellular proliferative disorders and use of compounds identified for such treatment.Type: ApplicationFiled: April 21, 2011Publication date: December 26, 2013Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Alexei Vazquez, Darren Carpizo, Arnold Levine
-
Patent number: 8613929Abstract: The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing early dynamic inflammation-induced changes in blood-brain bather functionality. Such polypeptides are referred to as lipopolysaccharide-sensitive (LPSS) polypeptides. These nucleic acids and polypeptides may be useful in methods for controlling blood-brain bather properties in mammals in need of such biological effects. This includes the diagnosis and treatment of disturbances in the blood-brain/retina barrier, brain (including the eye) disorders, as well as peripheral vascular disorders. Additionally, the invention relates to the use of anti-LPSS polypeptide antibodies or ligands as diagnostic probes, as blood-brain barrier targeting agents or as therapeutic agents as well as the use of ligands or modulators of expression, activation or bioactivity of LPSS polypeptides as diagnostic probes, therapeutic agents or drug delivery enhancers.Type: GrantFiled: July 21, 2011Date of Patent: December 24, 2013Assignee: TO-BBB Holding B.V.Inventors: Pieter J. Gaillard, Albertus G. De Boer, Arjen Brink
-
Patent number: 8609640Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.Type: GrantFiled: July 25, 2008Date of Patent: December 17, 2013Assignee: Eisai, Inc.Inventors: Sergei Agoulnik, Bruce Decosta, Hong Du, Yimin Jiang, Xiang-Yi Li, Kenichi Nomoto, John (Yuan) Wang, Huiming Zhang, Jiayi Wu
-
Patent number: 8609716Abstract: A composition comprising a substantially purified compound of the formula: in combination with at least one additional therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase.Type: GrantFiled: October 1, 2012Date of Patent: December 17, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Michael R. Boyd, Kirk R. Gustafson
-
Publication number: 20130331323Abstract: A compound for controlling blood glucose level has a structure shown in Formula I: wherein R5-R8 are as defined herein. A method for controlling blood glucose level includes administering to a subject in need thereof a compound of Formula I. The method further includes administering to the subject a GLP-1 receptor ligand. The compound and the GLP-1 receptor ligand may be administered together. The compound may be Galanal A or Galanal B. The GLP-1 receptor ligand may be GLP-1 or exendin-4.Type: ApplicationFiled: June 6, 2013Publication date: December 12, 2013Applicant: Development Center for BiotechnologyInventors: Rey-Yuh Wu, Hui-Ling Chen, Yu-Yuan Wu, Jiann-Jyh Huang, Shoei-Sheng Lee, K-Lim King
-
Publication number: 20130331444Abstract: The present disclosure provides methods of treating a cognitive disorder associated with abnormal dendritic spines, such as Fragile X Syndrome, Fragile X Associated Tremor/Ataxia Syndrome, autism, or mental retardation, using PKC activators.Type: ApplicationFiled: August 19, 2011Publication date: December 12, 2013Applicant: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTEInventors: Miao-kun Sun, Daniel L. Alkon
-
Publication number: 20130324595Abstract: The present invention concerns a C-glucosidic ellagitannin compound or a metabolite thereof for use for altering the supramolecular arrangement of actin in an individual suffering from osteoporosis, cancer, bacterial infection, or viral infection. It also pertains to pharmaceutical compositions comprising a C-glucosidic ellagitannin compound and/or metabolites thereof and one or more physiologically acceptable carriers. It finally concerns a C-glucosidic ellagitannin compound or a metabolite thereof, optionally detectably labeled, for in vitro use as a tool for studying cellular mechanisms involving actin, or for detecting F-actin in a cell.Type: ApplicationFiled: February 22, 2012Publication date: December 5, 2013Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Stephane Quideau, Elisabeth Genot, Frederic Saltel, Celine Douat, Daniela Melanie Delannoy Lopez
-
Publication number: 20130324481Abstract: This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably ?-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.Type: ApplicationFiled: August 9, 2013Publication date: December 5, 2013Applicant: Ramscor, Inc.Inventors: Vernon G. Wong, Louis L. Wood
-
Publication number: 20130324577Abstract: Provided is a compound which has strong and sustaining intraocular pressure lowering action and, further, has no fear of side effect on eyes. Since a compound represented by the formula (I): wherein definition of each group is as described in the specification, or a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering action and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.Type: ApplicationFiled: January 26, 2012Publication date: December 5, 2013Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Tohru Kambe, Isamu Sugimoto
-
Patent number: 8598221Abstract: The present invention relates to a pharmaceutical composition comprising as active substances: at least one compound of the following general formula (I): and at least one inhibitor of type 2 cyclooxygenase (COX-2), notably for use in the prevention or treatment of pain.Type: GrantFiled: December 3, 2010Date of Patent: December 3, 2013Assignee: BiocodexInventors: Philippe Girard, Marie-Emmanuelle Le Guern, Jean-Marie Gillardin, Bernard Hublot
-
Publication number: 20130317095Abstract: The invention demonstrates the application of an artemisinin derivative and its pharmaceutical salt. The artemisinin derivatives diarteether amine and its pharmaceutical salt inhibit the proliferation of leukemic cells, block the cell cycle of leukemic cells and induce the apoptosis of leukemic cells. Artemisinin derivatives of the present invention and its pharmaceutical salt can be used for the preparation of anti-leukemia medicines, especially for treatment of acute leukemia and, what's more, for the treatment of acute myeloid leukemia.Type: ApplicationFiled: January 16, 2012Publication date: November 28, 2013Applicant: Shanghai Institute of Materia Medica, Chinese Academy of SciencesInventors: Jianqing Mi, Ying Li, Yu Peng, Yu Zhang, Ruimin Nie, Jingjing Liu, Jin Wang, Yueying Wang, Xun Cai, Yang Li, Saijuan Chen, Zhenyi Wang
-
Publication number: 20130317094Abstract: Described herein are materials and methods for the inhibition of bacterial QS. Methods of treating bacterial infections by administration of one or more ellagitannins in amount effective to inhibit bacterial QS is also provided.Type: ApplicationFiled: May 14, 2013Publication date: November 28, 2013Applicant: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEESInventors: Kalai Mathee, Allison L. Adonizio, Frederick Ausubel, Jon Clardy, Bradley Bennett, Kelsey Downum
-
Publication number: 20130316906Abstract: The invention relates to novel compounds of the formula (I) in which R1, R2, R3, R4, R5, Y, Q and G have the meanings given above, to a plurality of processes and intermediates for their preparation and to their use as herbicides and/or pesticides. Moreover, the invention relates to selective herbicidal compositions comprising, firstly, the phenyl-substituted bicyclooctane-1,3-dione derivates and, secondly, a crop plant compatibility-improving compound. The present invention furthermore relates to increasing the activity of crop protection compositions comprising in particular phenyl-substituted bicyclooctane-1,3-dione derivates by adding ammonium salts or phosphonium salts and, if appropriate, penetrants, to the corresponding compositions, to processes for their preparation and to their use in crop protection as pesticides and/or for preventing unwanted plant growth.Type: ApplicationFiled: October 28, 2011Publication date: November 28, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Alfred Angermann, Stefan Lehr, Guido Bojack, Reiner Fischer, Isolde Häuser-hahn, Ines Heinemann, Elmar Gatzweiler, Christopher Hugh Rosinger, Arnd Voerste, Dieter Feucht
-
Patent number: 8592611Abstract: The disclosure provides novel trioxane sulfur dimers having Formula I: methods for their preparation, pharmaceutical compositions containing these compounds, and methods for treating cancer, proliferative disorders, and/or malaria using these compounds and/or compositions.Type: GrantFiled: July 17, 2009Date of Patent: November 26, 2013Assignee: The Johns Hopkins UniversityInventors: Gary H. Posner, Andrew S. Rosenthal
-
Publication number: 20130303600Abstract: The present invention relates to an anti-angiogenic composition containing macrolactin compounds such as macrolactin A, 7-O-malonyl macrolactin A, and 7-O-succinyl macrolactin A as active ingredients. The macrolactin compounds according to the present invention strongly suppress angiogenesis in in vivo experiments and can be used as a pharmaceutical composition for preventing or treating diseases caused by angiogenesis.Type: ApplicationFiled: July 15, 2013Publication date: November 14, 2013Applicant: DAEWOO PHARMACEUTICAL IND. CO., LTD.Inventors: Young-Hoon JI, Dong-Hee KIM, Jung-Ae KIM, Jae-Seon KANG, Sung-Uk CHUNG, Sung-Woo HWANG, Kyung-Ran KANG, You-Ra KANG
-
Publication number: 20130303489Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 11, 2013Publication date: November 14, 2013Applicant: Eisai R&D Management Co., Ltd.Inventors: Sergei Agoulnik, Bruce Decosta, Hong Du, Yimin Jiang, Xiang-Yi Li, Kenichi Nomoto, John (Yuan) Wang, Huiming Zhang
-
Publication number: 20130296412Abstract: The present invention relates to novel artemisinin-like derivates, and especially dihydroartemisinin derivates and pharmaceutical compositions comprising the present compounds. The present invention further relates to the use of the present compounds for the treatment of cancer, especially by oral administration. Especially, the present invention relates to dihydroartemisinin compounds (DHA) substituted by, through an ester linkage by a linear or branched C1 to C6 alkyl optionally substituted by one or more halogens. Especially preferred substituents are acetate, propionate, isopropionate, butyrate and isobutyrate.Type: ApplicationFiled: August 3, 2011Publication date: November 7, 2013Applicant: DAFRA PHARMA N.V.Inventor: Frans Herwig Jansen
-
Publication number: 20130296413Abstract: Desmethyldoxepin, isomers of desmethyldoxepin, and pharmaceutically acceptable salts and prodrugs of desmethyldoxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders.Type: ApplicationFiled: July 2, 2013Publication date: November 7, 2013Inventors: Neil B. Kavey, Susan E. Dube
-
Publication number: 20130296373Abstract: The disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides.Type: ApplicationFiled: May 6, 2013Publication date: November 7, 2013Applicant: Dow AgroSciences LLCInventors: Kevin G. Meyer, W. John Owen, James M. Renga, Chenglin Yao, Benjamin M. Nugent, Jeremy Wilmot, Fangzheng Li, Karla Bravo-Altamirano
-
Publication number: 20130296375Abstract: The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides.Type: ApplicationFiled: May 6, 2013Publication date: November 7, 2013Applicant: Dow AgroSciences LLCInventors: Kevin G. Meyer, Karla Bravo-Altamirano, James M. Renga, Jessica Herrick, Benjamin M. Nugent, Timothy A. Boebel, Fangzheng Li, Nick X. Wang, W. John Owen, Paul R. Graupner, Chenglin Yao, Ronald J. Heemstra
-
Publication number: 20130296411Abstract: In certain aspects, the invention relates to methods of treating proliferative cervical disorders (such as cervical cancer and cervical dysplasia) and treating virus infection by administering artemisinin-related compounds. In certain aspects, the invention relates to methods of treating a tumor induced by an oncogenic virus, methods of killing or inhibiting a squamous cell carcinoma, and methods of inhibiting the replication of a virus, by administering artemisinin-related compounds.Type: ApplicationFiled: February 26, 2013Publication date: November 7, 2013Inventors: Richard SCHLEGEL, Dan-Paul HARTMANN, Astrid BAEGE
-
Patent number: 8575211Abstract: The present invention relates to a pharmaceutical composition comprising as active substances: at least one compound of the following general formula (I): and at least one compound of the following general formula (V): especially for its use in the prevention or treatment of pain.Type: GrantFiled: October 28, 2009Date of Patent: November 5, 2013Assignee: BiocodexInventors: Philippe Girard, Marie-Emmanuelle Le Guern, Laurence Berthon-Cedille, Jean-Marie Gillardin, Bernard Hublot
-
Publication number: 20130289102Abstract: The present invention relates to formulations comprising amyris alcohol or an ester of amyris alcohol or combinations thereof to treat acne in humans. These formulations can further comprise a phytoestrogen such as glabridin and miroestrol, an antioxidant such as tetrahydrocurcumin and naturally occurring peroxides such as artemisinin and dihydroartemisinin and combinations thereof for improved effectiveness in treating acne.Type: ApplicationFiled: December 22, 2011Publication date: October 31, 2013Applicant: Trinity Laboratories, Inc.Inventors: Chandra Ulagaraj Singh, Jagaveerabhadra Rao Nulu
-
Publication number: 20130281391Abstract: The present invention provides a composition having an excellent controlling activity on a pest. The composition comprising a compound represented by Formula (1) and one or more macrolide compound(s) selected from Group (A) shows an excellent controlling activity on a pest.Type: ApplicationFiled: October 27, 2011Publication date: October 24, 2013Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: So Kiguchi, Soichi Tanaka
-
Patent number: 8551507Abstract: Several terpene glycosides (e.g., mogroside V, paenoiflorin, geniposide, rubusoside, rebaudioside A, steviol monoside and stevioside) were discovered to enhance the solubility of a number of pharmaceutically and medicinally important compounds, including but not limited to, paclitaxel, camptothecin, curcumin, tanshinone HA, capsaicin, cyclosporine, erythromycin, nystatin, itraconazole, celecoxib, clofazimine, digoxin, oleandrin, nifedipine, and amiodarone. The use of the diterpene glycoside rubusoside and monoterpene glycoside paenoiflorin increased solubility in all tested compounds. The terpene glycosides are a naturally occurring class of water solubility-enhancing compounds that are non-toxic and that will be useful as new complexing agents or excipients in the pharmaceutical, agricultural (e.g., solubilizing pesticides), cosmetic and food industries.Type: GrantFiled: June 24, 2010Date of Patent: October 8, 2013Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical CollegeInventor: Zhijun Liu
-
Publication number: 20130259936Abstract: The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.Type: ApplicationFiled: May 20, 2013Publication date: October 3, 2013Inventors: Luigi Schioppi, Brian Talmadge Dorsey, Michael Skinner, John Carter, Robert Mansbach, Philip Jochelson, Roberta L. Rogowski, Cara Casseday, Meredith Perry, Bryan Knox
-
Publication number: 20130261174Abstract: The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Stereocaulon alpinum. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.Type: ApplicationFiled: July 1, 2011Publication date: October 3, 2013Applicant: KOREA OCEAN RESEARCH AND DEVELOPMENT INSTITUTEInventors: Joung Han Yim, Il Chan Kim, Doc Kyu Kim, Se Jong Han, Hyoung Seok Lee, Bhattarai Hari Datta, Jung Eun Kim, Tai Kyoung Kim, Hyun Cheol Oh, Dong-Gyu Jo, Cheolsoon Lee, Keun-Sik Kim, Pyung Cheon Lee, Mi Ra Park, Yu-Kyung Park, Sung Jin Kim, Pil-Sung Kang, Heeyong Park, Ha Ju Park
-
Publication number: 20130252909Abstract: The invention provides a method to prevent or treat HIV-infection with synthetic tannins, and pharmaceutical compositions comprising synthetic tannins.Type: ApplicationFiled: March 7, 2013Publication date: September 26, 2013Applicant: University of Iowa Research FoundationInventors: George A. Kraus, Wendy Maury
-
Patent number: 8541019Abstract: The present invention is directed to palatable ductile chewable veterinary composition for oral administration. The composition is capable of killing endo-parasites and ecto-parasites and/or can be used for treating prophylactic or curative animal diseases, and it is useful for the treatment of any warm-blooded non-human animal, including herd animals, like horses, cattle, sheep or poultry and preferably pets like dogs and cats. It consists basically of (A) an effective amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; (B) meat flavoring; (C) partially gelatinized starch; (D) a softener; and (E) up to 9% water.Type: GrantFiled: October 31, 2011Date of Patent: September 24, 2013Assignee: Novartis AGInventor: Ute Isele
-
Publication number: 20130245108Abstract: An object of the present invention is to provide a novel antischistosomal agent, and more specifically, to provide a novel drug capable of inhibiting a growth of schistosomes in vivo to prevent development of liver dysfunction due to eggs of the schistosomes in the case of infection with the schistosomes. The novel antischistosomal agent includes as an active ingredient a peroxide derivative. Specifically, the novel antischistosomal agent includes as an active ingredient a peroxide derivative represented by the general formula (I): where C represents an alicyclic hydrocarbon ring group which may be substituted, and n represents an integer of 1 to 6.Type: ApplicationFiled: April 26, 2013Publication date: September 19, 2013Applicant: National University Corporation Okayama UniversityInventors: Yusuke Wataya, Hye-Sook Kim, Akiko Hiramoto, Akira Sato, Nobuo Ota, Takashi Kumagai, Rieko Shimogawara, Toshie Taniguchi
-
Publication number: 20130237560Abstract: A method of inhibiting excitotoxicity by indirectly activating ?4?2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed. Inhibitors of ?7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate ?4?2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.Type: ApplicationFiled: March 15, 2013Publication date: September 12, 2013Inventors: Peter Andrew Ferchmin, Vesna Ana Eterovic De Ferchmin, Hector Manuel Maldonado
-
Publication number: 20130236573Abstract: The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a therapeutically effective amount of esketamine as mono-therapy or as combination therapy with at least on antidepressant.Type: ApplicationFiled: March 12, 2013Publication date: September 12, 2013Inventors: Jaskaran Singh, Ivo Caers
-
Publication number: 20130231384Abstract: The present invention provides methods of slowing or reversing the loss of memory and learning comprising the steps of contacting an effective amount of a PKC activator with a protein kinase C (PKC) in a subject identified with memory loss slowing or reversing memory loss. The present invention provides methods of stimulating cellular growth, neuronal growth, dendritic growth, dendritic spine formation, dendritic spine density, and the translocation of ELAV to proximal dendrites, and synaptic remodeling. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC.Type: ApplicationFiled: September 27, 2012Publication date: September 5, 2013Applicant: BLANCHETTE ROCKEFELLER NEUROSCIENCE INSTITUTEInventor: Daniel L. Alkon
-
Publication number: 20130231371Abstract: A spot-on pesticide composition for animals, specifically mammals, namely dogs, which composition comprises a combination of a pyrethroid and a macrocyclic lactone selected from avermectin, ivermectin, selamectin, moxidectin, milbemycin and any combination thereof, and optionally fipronil and/or an insect growth regulator, in doses and proportions which are parasiticidally effective against a variety of insects and pests, and in a formulation which is convenient for local application to the animal's skin, preferably localized over a small surface area.Type: ApplicationFiled: April 5, 2013Publication date: September 5, 2013Applicant: Sergeant's Pet Care Products, Inc.Inventors: Larry Nouvel, Donald W Kelley
-
Publication number: 20130224295Abstract: It is an object of the present invention to provide a powder, a granule, an orally-disintegrating tablet, and the like that contain a drug causing bitterness, and that can suppress the bitterness in the mouth and improve solubility thereof in the stomach. The present invention provides a drug-containing granule comprising (a) a core particle that contains a drug causing bitterness, and (b) a masking coating that coats the core particle, wherein the masking coating contains: at least one polymer selected from methacrylic acid copolymer S, methacrylic acid copolymer L, methacrylic acid-ethyl acrylate copolymer, ethyl acrylate-methyl methacrylate copolymer, and ethyl acrylate-methyl methacrylate-ethyl ammonium trimethyl chloride methacrylate copolymer; and at least one diluent selected from D-mannitol, lactose, trehalose, xylitol, maltitol, and erythritol, an orally-disintegrating tablet comprising the drug-containing granule, and the like.Type: ApplicationFiled: April 8, 2011Publication date: August 29, 2013Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Yuji Miyamoto, Takuya Tokuda, Motohiro Ota, Yasuhiro Ishikawa
-
Publication number: 20130217673Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of mixed monoamine reuptake inhibitor locally at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least thirty days. In some embodiments, the relief can be for at least at least fifty days, at least one hundred days, at least one hundred and twenty days, at least one hundred and thirty, at least one hundred fifty days or at least one hundred and eighty days.Type: ApplicationFiled: February 22, 2012Publication date: August 22, 2013Applicant: Warsaw Orthopedic, IncInventor: Jared T. Wilsey
-
Patent number: 8513299Abstract: Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).Type: GrantFiled: May 18, 2007Date of Patent: August 20, 2013Assignees: Pernix Sleep, Inc., Procom One, Inc.Inventors: Roberta L. Rogowski, Susan E. Dubé, Philip Jochelson
-
Patent number: 8513188Abstract: This invention relates to the use of a cyclic compound of formula (I) wherein A, B independently in each occurrence is alkane-i,j-diyl having k carbon atoms, i and independently j being less than or equal k and k being selected from 1 to 10, wherein said alkane-i,j-diyl (i) may comprise one or more double bonds; (ii) is optionally substituted; and/or (iii) comprises a cycle, wherein the total number of cycles being cyclic sugars in said compound is selected from 0 to 4 and is less than p·(n+m); X,Y independently in each occurrence is a biocompatible functional group comprising at least one oxygen atom or two sulphur atoms; n, m independently of each other are selected from 0 to 20; p is selected from 1 to 10; n+m is equal or greater than 1; and p·(n+m) is selected from 3 to 30; wherein said compound is capable of forming a complex with a protonated primary and/or protonated secondary amino group and/or a protonated guanidinium group for the manufacture of a pharmaceutical or diagnostic composition.Type: GrantFiled: September 27, 2007Date of Patent: August 20, 2013Inventor: Paolo Botti
-
Publication number: 20130210812Abstract: The present invention is an aqueous pharmaceutical composition that includes an ionized therapeutic agent, an ionic component and guar gum. The guar gum is present in the composition a concentration sufficient to limit interactions between the ionized therapeutic agent and the ionic component thereby imparting stability to the composition. The composition is preferably at or near physiologic pH. The aqueous pharmaceutical composition has been found particularly useful as an aqueous ophthalmic, otic or nasal composition. The pharmaceutical composition, due to its characteristics, is particularly suitable as an ophthalmic composition.Type: ApplicationFiled: February 8, 2013Publication date: August 15, 2013Applicant: Alcon Research, Ltd.Inventor: Alcon Research, Ltd.
-
Publication number: 20130210775Abstract: Provided is an agent for reducing odors of pyrazine derivatives based on an olfactory receptor antagonism. The agent for reducing odors of pyrazine derivatives includes at least one antagonist of olfactory receptor OR5K1 as an active ingredient.Type: ApplicationFiled: December 4, 2012Publication date: August 15, 2013Applicant: Kao CorporationInventor: Kao Corporation
-
Patent number: 8507698Abstract: The invention relates to Artemisinin derivatives of general formula (I) wherein A and B are as defined in the specification. Compounds (I) have proved able to inhibit cell proliferation, in particular of uveal melanoma cells, and can therefore be used, either alone or in association with other antitumoral drugs, for the preparation of medicaments intended for the treatment of malignant melanoma.Type: GrantFiled: September 25, 2008Date of Patent: August 13, 2013Assignee: Lachifarma S.R.L. Laboratorio Chimico Farmaceutico SalentinoInventors: Azzurra Villanova, Luciano Villanova, Felicia Cisale
-
Publication number: 20130203715Abstract: Methods are described for treating or preventing a respiratory infection by administering an effective amount of a TRP channel agonist.Type: ApplicationFiled: July 20, 2011Publication date: August 8, 2013Applicant: Pulmatrix, Inc.Inventors: David L. Hava, Robert W. Clarke
-
Publication number: 20130203701Abstract: The invention provides pharmaceutical compositions containing omega-3 oil and a non-hydrophilic co-solvent that have an increased absorption rate. The pharmaceutical compositions may further contain one or more pharmaceutical organic molecules. The invention further provides kits containing these pharmaceutical compositions, methods for formulating pharmaceutical compositions containing omega-3 oil, and methods for decreasing the likelihood of developing cardiovascular disease, decreasing triglyceride or LDL cholesterol levels, decreasing pain or inflammation, treating diabetes, chronic pulmonary diseases, or irritable bowel syndrome, decreasing symptoms of an autoimmune disease or allergic conditions.Type: ApplicationFiled: September 15, 2011Publication date: August 8, 2013Applicant: Maine Natural Health, Inc.Inventor: Harry J. Leighton
-
Patent number: 8501803Abstract: The present invention relates to a field of pharmaceutical chemistry, more specifically, the present invention relates to a garcinia derivative Formula (I), its preparing method, and medicinal use. Wherein the definitions of R1 and R2 are disclosed in the specification of the present invention, and the derivative of the present invention is a structurally simplified analogue of the gambogic acid compound; wherein the gambogic acid compound possesses anti-cancer characteristics, and could be used for preparation of anti-tumor drugs.Type: GrantFiled: November 9, 2010Date of Patent: August 6, 2013Assignee: China Pharmaceutical UniversityInventors: Qidong You, Xiaojian Wang, Qian Yang, Na Lu, Changjun Lin, Qinglong Guo
-
Publication number: 20130196987Abstract: The present invention provides compounds, methods for the synthesis thereof and methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis.Type: ApplicationFiled: October 30, 2012Publication date: August 1, 2013Applicant: EISAI CO., LTD.Inventors: Roch Boivin, Kenichi Chiba, Jesse Chow, Hong Du, Yoshihito Eguchi, Masanori Fujita, Masaki Goto, Fabian Gusovsky, Jean-Christophe Harmange, Atsushi Inoue, Yimin Jiang, Megumi Kawada, Takatoshi Kawai, Yoshiyuki Kawakami, Akifumi Kimura, Makoto Kotake, Yoshikazu Kuboi, Charles-Andre Lemelin, Xiang-Yi Li, Tomohiro Matsushima, Yoshiharu Mizui, Kenzo Muramoto, Hideki Sakurai, Yong-Chun Shen, Hiroshi Shirota, Mark Spyvee, Isao Tanaka, John (Yuan) Wang, Satoshi Yamamoto, Naoki Yoneda
-
Publication number: 20130196965Abstract: The invention relates to a compound of formula (I) wherein A, B, D and R1 to R6 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: January 10, 2013Publication date: August 1, 2013Applicant: HOFFMANN-LA ROCHE INC.Inventor: HOFFMANN-LA ROCHE INC.
-
Patent number: 8497298Abstract: The present invention is a method for the glucose related disorders and lipid related disorders comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) or formula (II) as herein defined. The present invention is further directed to methods of treatment comprising co-therapy with an anti-diabetic agent, and anti-lipid agent and/or an anti-obesity agent.Type: GrantFiled: December 18, 2006Date of Patent: July 30, 2013Assignee: Janssen Pharmaceutica NVInventors: Virginia L. Smith-Swintosky, Allen B. Reitz
-
Publication number: 20130184218Abstract: A targeted osmotic lysis (TOL) of tumor cells that over-express voltage-gated sodium channels (VGSCs) has been developed that uses a combined therapy of a drug that blocks sodium, potassium-adenosine triphosphatase (Na+, K+-ATPase) that is then followed by an activation of VGSCs, for example, by electrical or pharmacological stimulation. Activation of VGSCs conducts sodium into the cancer cells in much greater amounts than non-cancer cells. Water follows this sodium gradient into the cancer cells, causing swelling and lysis. Because non-cancerous cells do not over-express VGSCs, less sodium and less water will enter the cells, and the non-cancerous cells will not lyse. This method is applicable to all cells that over-express VGSCs, including, but not limited to, highly invasive breast cancer, prostate cancer, small cell lung cancer, non-small cell lung carcinoma, lymphoma, mesothelioma, neuroblastoma, and cervical cancer.Type: ApplicationFiled: July 19, 2012Publication date: July 18, 2013Inventors: Dennis J. Paul, Harry J. Gould